Crestwood Advisors Group LLC Has $35.65 Million Stake in Zoetis Inc. (NYSE:ZTS)

Crestwood Advisors Group LLC lowered its position in shares of Zoetis Inc. (NYSE:ZTS) by 1.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 218,775 shares of the company’s stock after selling 3,563 shares during the period. Crestwood Advisors Group LLC’s holdings in Zoetis were worth $35,645,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. IFP Advisors Inc increased its position in Zoetis by 13.0% during the 4th quarter. IFP Advisors Inc now owns 10,033 shares of the company’s stock worth $1,635,000 after buying an additional 1,158 shares during the period. Waverton Investment Management Ltd grew its stake in shares of Zoetis by 7.2% in the fourth quarter. Waverton Investment Management Ltd now owns 335,536 shares of the company’s stock valued at $54,707,000 after acquiring an additional 22,637 shares in the last quarter. New World Advisors LLC increased its position in Zoetis by 22.9% during the fourth quarter. New World Advisors LLC now owns 3,384 shares of the company’s stock worth $551,000 after acquiring an additional 631 shares during the period. Y Intercept Hong Kong Ltd bought a new position in Zoetis during the fourth quarter worth about $3,530,000. Finally, Union Bancaire Privee UBP SA acquired a new stake in Zoetis in the 4th quarter worth about $898,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

NYSE:ZTS opened at $160.39 on Monday. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The stock’s 50-day simple moving average is $166.51 and its 200 day simple moving average is $177.94. The firm has a market capitalization of $71.82 billion, a PE ratio of 29.32, a price-to-earnings-growth ratio of 2.78 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.25%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s payout ratio is presently 36.56%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ZTS. Leerink Partners started coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. Stifel Nicolaus reduced their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Morgan Stanley lowered their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. UBS Group initiated coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price for the company. Finally, Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and a consensus target price of $215.40.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.16% of the company’s stock.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.